Safety and Single-Dose Pharmacokinetics of Abacavir (1592U89) in Human Immunodeficiency Virus Type 1-Infected Children
W. William Hughes(St. Jude Children's Research Hospital), Seth Hetherington(Unknown), James A. McDowell(Research Triangle Park Foundation), William T. Symonds(Gilead Sciences (United States)), Patricia M. Flynn(St. Jude Children's Research Hospital), Yu Lou(Zhejiang Chinese Medical University), Mark W. Kline(Tulane University), Jerry L. Shenep(St. Jude Children's Research Hospital), Ram Yogev(Northwestern University)
Cited by 50
Related Papers
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.6k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Lymphocyte subsets in healthy children from birth through 18 years of age
|Journal of Allergy and Clinical Immunology|2003|828